Explore

Trendline Trendline
enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization

enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization

enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization
Trendline Trendline
Amgen Advances Thyroid Eye Disease Treatment with New Formulation

Amgen Advances Thyroid Eye Disease Treatment with New Formulation

Amgen Advances Thyroid Eye Disease Treatment with New Formulation
Trendline Trendline
Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions
Trendline Trendline
NurExone and BioXtek Sign LOI for Exosome Manufacturing Partnership in Florida

NurExone and BioXtek Sign LOI for Exosome Manufacturing Partnership in Florida

NurExone and BioXtek Sign LOI for Exosome Manufacturing Partnership in Florida
Trendline Trendline
FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma

FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma

FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma
Trendline Trendline
Anixa Biosciences CEO Discusses Cancer Immunotherapy Advances

Anixa Biosciences CEO Discusses Cancer Immunotherapy Advances

Anixa Biosciences CEO Discusses Cancer Immunotherapy Advances
Trendline Trendline
FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls
Trendline Trendline
Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus
Trendline Trendline
API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'
Trendline Trendline
API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development
Trendline Trendline
GenSight Biologics Confirms 2025 Financial Results Align with Estimates Amid Funding Challenges

GenSight Biologics Confirms 2025 Financial Results Align with Estimates Amid Funding Challenges

GenSight Biologics Confirms 2025 Financial Results Align with Estimates Amid Funding Challenges
Trendline Trendline
Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials